Business Wire

VERISILICON

15.5.2024 02:01:33 CEST | Business Wire | Press release

Share
Actions Technology’s Smart Watch SoC Adopted VeriSilicon’s 2.5D GPU IP

VeriSilicon (688521.SH) today announced that Actions Technology (688049.SH), a low-power AIoT fabless semiconductor company, has adopted VeriSilicon’s power-efficient and feature-rich 2.5D Graphics Processor Unit (GPU) IP in its highly integrated dual-mode Bluetooth smart watch SoC series, ATS3085S and ATS3089.

Featuring low power consumption and high frame rate, Actions Technology’s smart watch SoCs, ATS3085S and ATS3089 series, offer excellent graphics display performance with 2D+2.5D dual GPU hardware acceleration and support for JPEG hardware decoding. These SoCs, with their high level of integration, enable a single chip to drive display screens, run sports and health algorithms, perform Bluetooth calls, offer local audio decoding, and deliver Bluetooth audio transmission for True Wireless Stereo (TWS) headsets, providing mature dual-mode Bluetooth single-chip solutions supporting low-power Bluetooth 5.3 for end products such as smart bracelets and smart watches. Currently, smart watch products powered by ATS3085S and ATS3089 series SoCs have been mass-produced and launched in the market.

VeriSilicon’s 2.5D GPU IP is designed specifically for MCU and MPU applications that require hardware-accelerated User Interface (UI) display effects, and is capable of rendering vectors, scalars, and images in low-power modes, delivering high-performance, high-quality graphics processing capabilities and superior image output. It incorporates the company’s self-developed low-level, compact VGLite API driver to support the popular Light and Versatile Graphics Library (LVGL), enabling the creation of visually appealing UI across a wide range of hardware platforms and effectively reducing the size of their resources. The GCNanoUltraV 2.5D GPU also supports Scalable Vector Graphics (SVG) with VeriSilicon’s open-source tool SvgVGLiteRenderer, which parses SVG files and renders SVG content through the VGLite API. VeriSilicon’s 2.5D GPU IP has extended support for Baidu Maps and a variety of offline map formats, offering users a richer and more useful interactive experience.

Zhenyu Zhou, Chairman and CEO of Actions Technology, said, “VeriSilicon’s 2.5D GPU IP provides our smart watch SoCs with leading graphic rendering functions, enabling smoother UI interactions and appealing visual effects. The adoption of this technology significantly enhances the user experience of smart watches, meeting diverse needs of the global market, and thereby increasing our competitive advantages in the global wearable market.”

“As the resolutions and refresh rates of smart watch screens continue to improve, customers’ requirements for GPU performance are also increasing. VeriSilicon has effectively met the diverse needs of customers and drives the development of wearable applications through continuous technology innovation and actively building an ecosystem for key GPU applications,” said Wei-Jin Dai, Executive VP and GM of IP Division at VeriSilicon. “Our 2.5D GPU IP not only provides powerful graphics processing capabilities, but also enhances the performance-to-power ratio of Actions Technology’s smart watch SoCs to meet the needs of users who wear them for extended periods of time.”

About Actions Technology

Actions Technology (688049.SH) is a leading low-power AIoT fabless semiconductor company in China. We excel in providing high-quality and low-latency wireless audio experiences while prioritizing power efficiency. Our core expertise includes high-performance audio ADC/DAC, voice pre-processing, audio encoding/decoding, and audio post-processing technologies, enabling a superior audio signal chain. Additionally, we specialize in low-latency wireless connectivity with Bluetooth RF, baseband, and protocol stack technologies at the core. For more information about Actions® high-quality, low-latency platform, visit www.actionstech.com

About VeriSilicon

VeriSilicon is committed to providing customers with platform-based, all-around, one-stop custom silicon services and semiconductor IP licensing services leveraging its in-house semiconductor IP. For more information, please visit: www.verisilicon.com

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240514705930/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Galderma Provides Progress Update Regarding RelabotulinumtoxinA Regulatory Submission in the United States1.7.2026 07:00:00 CEST | Press release

Galderma received a Complete Response Letter from the FDA with comments related to observations during manufacturing site inspection and analytical method optimization Relfydess is approved in 33 markets and already launched in more than 20, including across Europe, the Middle East and Australia, with an encouraging early launch trajectory supported by positive healthcare professional feedback Regulatory filings in other territories are ongoing and remain on track Ad hoc announcement pursuant to Art. 53 LR Galderma (SIX: GALD) today provided progress updates regarding the regulatory review of its pending Biologics License Application (“BLA”) for RelabotulinumtoxinA with the U.S. Food and Drug Administration (“FDA”). The Company has received a Complete Response Letter (CRL) from the FDA with comments related to observations during manufacturing site inspection and analytical method optimization. As part of its review, the FDA conducted a Pre-License Inspection (PLI) of Galderma’s manufa

EVE Energy Showcases All-Scenario Energy Storage Solutions at The Smarter E Europe 20261.7.2026 03:45:00 CEST | Press release

EVE Energy unveiled its Mr. Big Family series, a 6.9+ MWh energy storage system, and all-scenario energy storage solutions at Intersolar Europe in Munich. Drawing on traceable large-cell technology, proven large-scale energy storage project delivery experience, and global delivery capabilities, the company is addressing Europe's diverse energy storage requirements across utility-scale, commercial & industrial (C&I ), and data center segments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260630889717/en/ EVE Energy showcases its Mr. Giant 3.0 6.9+ MWh energy storage system at The Smarter E Europe 2026 in Munich, Germany Advancing Large-Cell Technology with Global Project Validation As one of the first companies to focus on large-capacity energy storage cells, EVE Energy has iteratively upgraded its cell platform from 560 Ah and 628 Ah to 702 Ah, adhering to a stacking process route throughout. At the exhibition, the Mr. Gia

Bending Spoons S.p.A. announces pricing of initial public offering1.7.2026 01:56:00 CEST | Press release

Bending Spoons S.p.A. (“Bending Spoons”), a leading technology company, today announces the pricing of its initial public offering (“IPO”) at $29.00 per share. A total of 57,971,015 ordinary shares are being offered, of which 34,398,640 shares are being offered by Bending Spoons and 23,572,375 shares are being offered by certain selling shareholders (the “Selling Shareholders”). Bending Spoons will not receive any proceeds from any sale of shares by the Selling Shareholders. The shares are expected to begin trading on the Nasdaq Global Select Market under the ticker symbol “BSP” on July 1, 2026. The offering is expected to close on July 2, 2026, subject to customary closing conditions. In addition, Bending Spoons and the Selling Shareholders granted the underwriters an option to purchase up to an additional 5,244,026 ordinary shares from Bending Spoons and up to an additional 3,451,626 ordinary shares from the Selling Shareholders at the initial public offering price, less underwriting

FDA Issues Modified Risk Tobacco Product Orders for 20 ZYN Nicotine Pouch Products30.6.2026 18:19:00 CEST | Press release

FDA’s decision makes ZYN the first nicotine pouch product to receive MRTP orders authorizing reduced-risk claims versus cigarettes Philip Morris International Inc. (PMI) (NYSE: PM) today announced that the U.S. Food and Drug Administration (FDA) issued Modified Risk Tobacco Product (MRTP) orders for 20 variants of ZYN nicotine pouch products. These are the first MRTP orders granted for nicotine pouches, allowing PMI U.S. to market the following claim for the authorized ZYN products: “Using ZYN instead of cigarettes puts you at a lower risk of mouth cancer, heart disease, lung cancer, stroke, emphysema, and chronic bronchitis.” “FDA’s decision is an important moment for the more than 45 million legal-age nicotine consumers in America,” saidStacey Kennedy, PMI U.S. CEO. “Today’s news ensures these adultshave access to accurate, science-based information, including FDA-authorized evidence that switching from cigarettes to ZYN reduces the risk of smoking-related diseases like heart disease

Caidya Announces Strategic Combination with Simbec-Orion Bridging Early Scientific Insight and Global Clinical Execution30.6.2026 17:00:00 CEST | Press release

Caidya today announced a strategic combination with Simbec-Orion designed to close the divide between early scientific insight and global clinical execution. The combination of Caidya and Simbec-Orion creates a differentiated specialty clinical CRO platform that enables programs to scale, maintaining focus, speed, and accountability. The strategic combination brings together complementary strengths to create a more complete development partner for innovative biopharma companies. With established operations across Europe, the Americas, APAC, and China, the combined organization provides meaningful expertise and execution capabilities in the regions that matter most. Simbec-Orion brings early-phase clinical pharmacology capabilities alongside deep therapeutic expertise for later stage complex oncology and rare disease trials, helping sponsors shape critical decisions early in the development lifecycle. Together, the organizations strengthen their ability to support complex, cross-border

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye